Hepatocellular carcinoma is associated with substantial global mortality. Hepatocellular carcinoma ranks among the leading causes of cancer-related mortality worldwide, underscoring an urgent unmet clinical need (Llovet et al. 2021). Most patients still don’t survive beyond two years despite our best surgical techniques and newest drugs like sorafenib and lenvatinib (Finn et al. 2020). The issue isn’t that we lack treatments; it’s all due to cancer cells exhibiting diverse resistance mechanisms. For decades, scientists focused on apoptosis, a process which is focused on forcing cancer cells to commit suicide. Still this cellular poor prognosis resistance was learned by liver cancer cells by building a molecular shield that make traditional therapies nearly useless (Yang et al. 2019; Elmore et al., 2007). A breakthrough discovery was then made by scientists; they found two different ways by which cells can die, known as ferroptosis and cuproptosis (Stockwell et al. 2017; Chen et al. 2022). Ferroptosis occurs when iron builds inside cells and creates a toxic storm of molecules which are called lipid peroxides (Dixon et al. 2012). Lots of iron is required by cancer cells which eventually become their weakness. While copper accumulation in the cell’s power plant (mitochondria) and causing essential proteins to clump together by shutting down energy production is called cuproptosis (Chen et al. 2022). These discoveries are exciting as we can now use tiny metal particles called nanoparticles which can effectively deliver iron and copper accurately where we want them too, inside cancer cells but not healthy ones (Shi et al. 2017). In this review a complete story of how liver cancer develops its deadly tricks, how at molecular levels cuproptosis and ferroptosis work and how scientists are engineering metal nanoparticles to exploit these vulnerabilities. Also, we will explore why this approach could finally give us the upper hand against one of the medicine’s most challenging foes by potentially transforming liver cancer from a historically poor prognosis into a manageable disease (Anselmo and Mitragotri 2019). This schematic illustrates tumor-selective delivery of metal nanoparticles, triggering iron-driven lipid peroxidation (ferroptosis) and copper-induced mitochondrial toxicity (cuproptosis). The synergistic activation of these pathways overcomes therapeutic resistance in HCC. Collectively, this dual mechanism promotes efficient tumor cell death and highlights a promising therapeutic strategy.
Kaknale et al. (Fri,) studied this question.